The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,352,012 | - |
| Stock-based compensation expense | -741,858 | 6,040,136 |
| Issuance of common stock for services | 840,000 | - |
| Trade accounts payable and accrued liabilities | 74,419 | -332,580 |
| Prepaid expenses | -2,468 | 17,414 |
| Net cash used in operating activities | -927,264 | -1,559,577 |
| Payments to related party | - | 0 |
| Payments under related party line of credit | - | 0 |
| Proceeds from sale of common stock, related party | 3,000,000 | 0 |
| Proceeds from sale of common stock | 4,502,239 | 1,047,769 |
| Net cash flows provided by financing activities | 7,502,239 | 1,047,769 |
| Net change in cash | 6,574,975 | -511,808 |
| Cash and cash equivalents at beginning of period | 1,266,131 | - |
| Cash and cash equivalents at end of period | 7,329,298 | - |
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)